Pharma industry reports 105 deals worth $27 billion in September

The pharma industry has reported 53 deals worth $27.5 billion as compared to the last 12-month average (September 2020 to August 2021) of 105 deals worth $27 billion in September 2021.

Merck and Company, through its subsidiary Astros Merger Sub, has agreed to acquire Acceleron Pharma Inc, a biopharmaceutical company for $180 per share in cash for an approximate total equity value of $11.5 billion; Agnafit Bidco AB to acquire all shares of Swedish Orphan Biovitrum AB (Sobi), a biopharmaceutical company for a total consideration of $8 billion; and Perrigo Co Plc to acquire Laboratoire HRA Pharma SAS for a purchase consideration of approximately $2.1 billion, were the three major deals that contributed 78.8 per cent of the total deal value during September 2021.

The pharma industry reported 104 venture capital (VC) deals worth $3.5 billion in September 2021, compared to the last 12-month average (September 2020 to August 2021) of 173 deals worth $5.2 billion.

Trialspark Inc, a tech-driven drug development company, raising $156 million, in series C funding round to acquire and/or partner on clinical-stage pharmaceutical assets to develop through their in-house clinical trial platform; Mammoth Biosciences Inc, a biotech company raising $150 million, in series D round to build next-generation CRISPR products in therapeutics and diagnostics; and Provepharm life Solutions SA, raising $142.3 million to accelerate its internal development and external growth projects, were the major VC deals reported in September 2021.